CD8A and neoplasm: The administration of Alb-IFNβ in combination with our vaccinia virus encoding the HPV-16 E7 antigen (HPV vaccinia-based vaccine) enhanced antigen-specific CD8+ T cell immunity in a syngeneic TC-1 tumor model.